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Abstract
Oral valproic acid (VPA), which is a histone deacetylase inhibitor, was used in a phase II trial to treat patients with
castration-resistant prostate cancer (CRPC). Ten patients with CRPC were treated with oral VPA. Oral VPA was not
well tolerated in this patient population at a dose targeted to a serum level less than 50 μg/L. The main toxicities
were grades 1 and 2 neurologic events and grades 1 and 2 fatigue that caused interruption in the administration of
oral VPA and dose delays. Two (20%) of 10 patients had prostate-specific antigen (PSA) responses, and one re-
sponse was durable. Intensive biomarker collections (weekly) revealed that PSA levels were inversely correlated
with total VPA levels. Histone acetylation could not be consistently observed in peripheral lymphocytes using oral
VPA. Oral VPA can be administered to CRPC patients with resultant PSA responses. However, oral VPA cannot be
administered reliably to achieve consistent levels or duration to be useful in the treatment of CRPC patients. It is
unlikely that PSA responses from oral VPA are related to histone deacetylase inhibition. Development of oral VPA in
prostate cancers is not recommended using an oral formulation. An intensive biomarker strategy is useful to de-
velop clinical hypotheses in patients with CRPCs in small numbers of patients.
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Introduction
Castration-resistant prostate carcinoma (CRPC) is an aggressive dis-
ease with limited treatment options. Mitoxantrone plus prednisone is
an established chemotherapy regimen that has been shown to im-
prove pain in symptomatic patients but does not improve survival.
Several randomized studies have compared docetaxel-based regimens
to the mitoxantrone-based regimens and demonstrated a modest im-
provement in survival, making this treatment a standard of care for
this disease [1–4]. Despite these advances, the median survival of
CRPC remains only 18 to 20 months [2]. There is a clear need for
further improvements in therapy for CRPC. The investigation of
novel targeted agents is required because none of the above-mentioned
therapies are curative and do not offer long periods of palliation.
Histone deacetylase (HDAC) inhibition provides a novel approach
for cancer treatment. Histones are part of the core proteins in struc-
tures called nucleosomes. Acetylation and deacetylation of histones
plays a role in the regulation of gene expression. Deacetylated histones
are highly charged and bind tightly to DNA, inhibiting transcription.
This is presumably a result of limited access of transcription factors
and RNA polymerases to DNA. Acetylation, conversely, neutralizes
the charge of histones and generates a more open DNA conformation
[5]. This conformation allows transcription factors and associated
transcription apparatus access to the DNA, promoting expression of
the corresponding genes. A balance between the activity of two groups
of enzymes, histone acetyltransferase andHDAC, controls cell-specific
patterns of gene expression. Several lines of evidence suggest that ab-
errant recruitment of HDAC may result in modification of chromatin
and may play a role in changes in gene expression seen in transformed
cells [6–12]. Histone deacetylase inhibitors (HDAIs) have been shown
to induce differentiation and cell cycle arrest or apoptosis in cultured
tumor cells and to inhibit the growth of tumors in animal models [13–
20]. In addition, HDAIs have been shown to induce expression of p21,
a key mediator of G1 arrest and differentiation [21,22].
Valproic acid (VPA) is a commonly used antiseizure medication. It
has recently been shown to be an HDAI [23]. Similar to more widely
studied HDAIs, VPA can cause growth arrest and induce differentiation
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of transformed cells in culture. In addition, these authors found that
VPA and its analogs inhibit multiple HDACs from class I and class II
(but not HDAC6 or HDAC10). Valproic acid and its analogs also
induced hyperacetylation of core histones H3 and H4 in intact cells
with an order of potency that parallels in vitro inhibition. Valproic
acid and VPA analogs induced differentiation in hematopoietic cell
lines in a p21-dependent manner, and the order of potency for in-
duction of differentiation paralleled the potencies for inhibition and
for acetylation of histones associated with the p21 promoter, support-
ing the argument that differentiation caused by VPA was mediated
through inhibition of HDACs.
In another recently published study [24], VPA was used for ther-
apy for prostate cancer cell lines and also administered in vivo in
prostate cancer xenografts. The authors demonstrated that in con-
trast to acute treatment of VPA that increased net histone H3 acet-
ylation and up-regulated p21, androgen receptor (AR), and cytosolic
prostate-specific antigen (PSA) expression, chronic treatment led to
marked decreases in the net proliferation rate, correlating with in-
creased caspase-2 and caspase-3 activation and reversal of effects on
AR and PSA expression. Chronic administration of VPA also reduced
tumor burdens in xenograft models.
In the current study, we tested the feasibility and efficacy of treat-
ing men with CRPCs with oral VPA. In this particular trial, we
attempted to study the relationship between VPA levels, serum tes-
tosterone, serum PSA, and histone acetylation using an intensive
(weekly) sampling strategy for biomarkers.
Materials and Methods
Patients
Men at least 18 years, who signed informed consent and were di-
agnosed with prostatic adenocarcinoma, were considered for this
study. The clinical study was started in 2005 and was approved by
institutional review boards. All patients were enrolled after signing an
informed consent. Eligibility requirements included no more than
two prior chemotherapies, castrate levels of serum testosterone below
50 ng/ml, PSA progression (including baseline PSA levels at least
5.0 ng/ml), Karnofsky performance status of 70% or greater, and ad-
equate organ function. Men were excluded if they had a history of
liver disease, human immunodeficiency virus infection, seizure disor-
ders, or brain metastases. Additionally, men were excluded if they had
a myocardial infarction within the previous 6 months or evidence of
uncontrolled congestive heart failure. Men who were chemically cas-
trated were required to continue luteinizing hormone–releasing hor-
mone agonist therapy while on study.
Treatment
Valproic acid syrup was dispensed to patients orally at a concentra-
tion of 50 mg/ml. Drug was taken by mouth on a daily basis according
to the targeted dose level. The initial VPA dose was 10 mg/kg per day.
Within-patient dose escalation occurred weekly by 5 to 10 mg/kg per
day up to a maximum of 60 mg/kg per day provided that the total VPA
blood level of did not exceed 50 μg/L. This is consistent for dosing for
seizures (for which VPA is commonly used) because doses above this
level are commonly associated with neurologic toxicity). Valproic acid
dose reductions and delays were based on hematologic and nonhemato-
logic toxicities as described in the label of VPA for its seizure indication.
Treatment administration continued until disease progression, unac-
ceptable toxicity, or until withdrawal of consent by the patient.
Assessments
Patients were seen weekly during the first 8 weeks of VPA therapy
and at the investigator’s discretion thereafter. Assessments made dur-
ing study visits included performance status, physical examination,
hematology, and clinical chemistry.
Biomarker Assessment Strategy
To study the relationship among PSA, serum testosterone, VPA
blood levels, and histone acetylation, samples were collected be-
fore treatment and weekly (while on therapy). This strategy allowed
large numbers of samples to test for variation of these parameters
throughout the course of therapy and statistical analyses of treat-
ment effects.
Histone Acetylation
Histone acetylation was studied using a modification of an ELISA
assay already described [25]. Patient samples were collected and lym-
phocytes extracted using standard mononuclear cell extraction tubes
and stored at −80°C. For histone extraction, cells were resuspended
in triton extraction buffer (TEB: PBS containing 0.5% Triton X-
100, 2 mM phenylmethanesulfonyl fluoride, 0.02% NaN3) at a cell
density of approximately 1 × 107 cells per milliliter. Cells were lysed
on ice for 10 minutes with gentle mixing and then centrifuged at
4800g for 10 minutes at 4°C. The supernatant was discarded, and
the cell pellet was washed with TEB. The pellet was resuspended
in 0.2 N HCl at a cell density of approximately 4 × 107 cells per
milliliter, and histones were acid-extracted overnight at 4°C. The su-
pernatant containing histones was collected by centrifugation at
4800g for 10 minutes and stored at 4°C, and protein concentration
was determined using the BCA assay (23235; Pierce, Rockford, IL).
Histone extracts, 100 ng per well, were added to duplicate wells of
Immulon Microtiter 2HB ELISA plates (3455; Thermo, Waltham,
MA), resuspended in 0.2 N HCl to a final 50-μl volume. Plates were
incubated overnight at 4°C on a rocking platform shaker at 300 rpm.
After incubation, the plates were washed three times with 150 μl 1×
PBS + 0.05% Tween, blocked with 100 μl PBST + 3% nonfat dry
milk + 1% goat serum, and incubated for 1 hour at room temperature
on a rocking platform shaker at 300 rpm. The antibodies were diluted
in antibody dilution buffer, PBST + 1% goat serum, at a concentration
of 0.05 μg/ml for acetylated H3 (06-599; Upstate, Billerica, MA) and
1:1000 for Histone H3 (9715; Cell Signaling Technology, Danvers,
MA) and 50 μl of the antibody solution is added to each well. The
plates were incubated for 2 hours at room temperature on a rocking
platform shaker at 300 rpm. The plates were washed with PBST three
times at 5 minutes each on a shaker at 300 rpm. Goat anti-rabbit HRP
(SAB-300; Stressgen, Ann Arbor, MI) secondary antibody, diluted
to 1:10,000 in the antibody dilution buffer, was added at 50 μl per
well. The plates were incubated for 1 hour at room temperature on
a shaker at 300 rpm subsequently washed with 150 μl PBST four times
at 5 minutes each time, on a shaker at 300 rpm. The ELISAwas visual-
ized using the TMB Peroxidase EIA Substrate Kit (172-1066; BioRad,
Hercules, CA) according to the manufacturer’s instruction. The plate
was incubated on a rocking platform shaker on low speed until develop-
ment, and approximately 10minutes later, the plate was read at 655 nm
on the Biotek μQuant plate reader (Biotek Instruments, Winooski,
VT). Positive controls were used using cell lines (NCI H2452) treated
with various HDAIs including VPA. Additional positive controls in-
cluded treatment of extracted mononuclear cells ex vivo with VPA. Ap-
propriate negative controls were also used to optimize the assay.
142 Valproic Acid in Prostate Cancer Sharma et al. Translational Oncology Vol. 1, No. 3, 2008
Statistical Considerations
This was an open-label, single-institution, single-arm, two-stage
phase II study in patients with CRPCs. If at least one responder
among the first 19 patients was observed, an enrollment of an addi-
tional 20 patients was planned for stage 2. This study had approxi-
mately 85% power to exclude a response rate of 15% in favor of a
35% response rate with a nominal false-positive rate of 0.05.
Prostate-specific antigen response to therapy and disease progres-
sion was based on the criteria of Bubley et al. [26]. A PSA response
required at least a 50% reduction with a confirmation of at least
4 weeks later. The response duration was calculated from the time
of the first 50% reduction until the time of 50% increase in PSA
over nadir, provided the increase was at least 5 ng/ml (or returned
to baseline) and was confirmed. Nonresponding patients were pro-
gressed at the time of 25% increase over baseline or nadir, provided
the increase was at least 5 ng/ml and was confirmed.
Kaplan-Meier techniques [27] were used to summarize time to
PSA progression. Repeated measures analysis including patient as a
random factor was conducted to compare PSA values between re-
sponders and nonresponders. Spearman correlation coefficients were
calculated to assess factors that were individually associated with PSA
levels. Factors included VPA exposure (both VPA levels and duration
of treatment exposure) and serum testosterone. Multiple regression
analysis using both stepwise and backward elimination techniques
(α = 0.10 for variable entry and elimination) were used to identify
factors that were independently correlated with PSA.
Results
Patient Characteristics
From April 22, 2005 to July 24, 2006, 19 men signed informed
consent and 10 received VPA. Nine patients were ineligible because
they withdrew consent or did not have PSA elevations consecutively
as required by the study. A summary of patient characteristics for the
10 treated patients is shown in Table 1. All patients were hormone
refractory at time of enrollment. Nine of 10 patients had metastatic
disease at the time of enrollment.
Study Drug Administration
A summary of dose administration is shown in Table 2. All pa-
tients received at least 7 consecutive days of 10 mg/kg per day of
VPA before their first intrapatient dose escalation. Including days
of omitted or head doses, the average daily dose ranged from 10 to
19 mg/kg per day. A summary of the number of days of treatment by
dose level is shown in Table 3. Seven patients either omitted doses or
had doses held. These patients had a median of 7 days of omitted
doses, ranging from 1 to 21 days. At least seven of the ten patients
were escalated to 20 mg/kg per day of VPA.
Adverse Events
The main toxicity of VPA was neurologic and constitutional.
There were numerous [11] drug-related grade 1 and 2 neurologic
events (Table 4). These ranged from confusion, dizziness, fatigue,
somnolence to tremor, and frank drowsiness. These events seemed
to be unrelated to the serum levels of VPA (total or free). Neurologic
events were the most likely reasons for dose delays and withheld
doses in the study. Constitutional symptoms such as fatigue was
common. Fatigue seemed to be most related to length of administra-
tion of VPA. One patient died during the treatment administration
period. This death was related to disease progression and was not
study drug–related. An additional patient experienced a serious ad-
verse event (hypoxia). Although possible relationship to VPA could
not be ruled out, it is more likely that the hypoxia was related to
smoking history.
Overall, VPA seemed to be tolerated relatively poorly in this older
population and constant dose titration was required. Study accrual
was terminated because of poor tolerance of VPA and inability to
consistently titrate the dose of VPA to maintain the. within-patient
total VPA blood level of <50 μg/L.
Efficacy
Individual patient data for PSA response and progression is shown
in Table 5. Among the 10 evaluable patients, one patient (patient
Table 1. Patient and Baseline Disease Characteristics (N = 10).
Age (years)
Median (range) 71 (48-80)
Race (no. patients)
White 10
Performance status (no. patients)
100 2
90 2
80 4
70 1
60 1
Diagnosis (no. patients)
Prostatic adenocarcinoma 10*
Stage (no. patients)
Metastatic 9
Gleason score (no. patients)
5 1
6 1
7 2
8 2
9 1
n/a 3
Prior treatment (no. patients)
Chemotherapy 9
Surgery 3
Radiation 4
PSA (ng/ml)
Median (range) 33.8 (5.5-731.6)
Testosterone (ng/dl)
Median (range) 26 (16-48)
*Pathology report for two patients unavailable.
Table 2. Average Daily Dose of VPA and Days on Treatment.
Average Daily Dose
(mg/kg per day)
Days of Treatment
(no. days)
Including skipped doses, median (range) 13.4 (10-19) 51 (14-633)
Excluding skipped doses, median (range) 14.9 (10-19) 38.5 (14-626)
Table 3. Days of Treatment by Dose Level (N = 10).
Dose Level (mg/kg per day) Number of Patients Number of Days of Treatment
Minimum Median Maximum
10 10 7 14 424
15 8 7 12.5 181
20 7 7 13 49
25 4 2 7 14
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number 5) had a confirmed PSA response with no evidence of sub-
sequent progression. However, after a 29-day documented remission
period, the patient withdrew consent due to unacceptable neurologic
toxicity and was lost to follow-up. A second patient (patient num-
ber 6) demonstrated a PSA response with a duration of 471 days.
This patient was stable for 632 days and, after which, withdrew con-
sent because of constitutional symptoms. The remaining eight patients
had documented PSA disease progression, seven of whom did not have
a PSA nadir. With 80% of events observed, the median time to progres-
sion was 17.5 days, and the interquartile range was 7 to 292 days.
Pharmacodynamics
Figure 1 shows levels of total histone 3 and acetylated histone 3, ex-
pressed as a percent of baseline total histone 3. Acetylated histone 3 did
not increase over time suggesting that oral administration of VPA may
not be able to consistently cause histone acetylation in lymphocytes.
Biomarker Analysis
A plot of PSA as a percent of baseline is shown in Figure 2. A
repeated-measures analysis showed responding patients on treatment
had significantly lower PSA (P = .011) values on average. In a recent
publication from the prostate cancer clinical trials working group
[28], it was recommended that the percentage of change in PSA from
baseline to 12 weeks (or earlier for those who discontinue therapy)
and the maximum decline in PSA that occurs at any point after treat-
ment be reported for each patient using a waterfall plot. Accordingly,
the waterfall plot is depicted in Figure 3 for this trial. Accordingly,
the waterfall plot is depicted in Figure 3. As is evident from this
plot, three patients had any decline in PSA in this trial with only
two patients having a <50% decline.
Table 6 shows correlations relating PSA levels to VPA exposure
(levels and duration) and serum testosterone levels. Increasing VPA
levels were associated with decreasing PSA (Figure 4); however, the
correlation was stronger with total VPA than with free VPA. The du-
ration of VPA exposure was also negatively correlated with PSA val-
ues. Concurrent with decreasing (increasing) PSA values was a trend
for increasing (decreasing) serum testosterone levels.
These individual correlations were examined further to identify
factors that independently correlated with PSA. Multiple regression
analyses, using both stepwise and backward elimination techniques,
resulted in a final model that included total VPA (P < .001) and du-
ration of VPA exposure (P = .002) as independent predictors of de-
clining PSA. Serum testosterone was not independently predictive of
PSA (P = .399).
Threshold analyses were conducted for total VPA level and dura-
tion of exposure to identify VPA and duration values resulting in the
largest dichotomy between high and low PSA values (Figure 5). The
geometric mean of the PSA values for samples corresponding to total
VPA less than or equal to 46 mg/L was 59.6 ng/ml and was 11.7 ng/ml
Table 4. Summary of Common Toxicity Criteria Adverse Events.
Event Grades 1 and 2 Grade 3 Grade 4
Laboratories
Hemoglobin 1 1 0
Lymphopenia 1 0 0
Glucose, elevated (serum) 1 0 0
Neurology
Confusion 2 0 0
Dizziness 3 0 0
Memory impairment 1 0 0
Neurology other (drowsiness) 2 0 0
Somnolence 2 0 0
Tremor 1 0 0
Gastrointestinal
Anorexia 5 0 0
Constipation 1 0 0
Dental (periodontal disease) 1 0 0
Dry mouth 1 0 0
Other – thirst 1 0 0
Heartburn 1 0 0
Nausea 2 0 0
Vomiting 2 0 0
Constitutional
Fatigue 5 2 0
Fever 1 0 0
Rigors 0 1 0
Weight loss 1 0 0
Cardiac
Cardiac arrhythmia (other tachycardia) 1 0 0
Pulmonary
Dyspnea 3 0 0
Hypoxia 1 1 0
Lymphatics
Edema (limb) 3 0 0
Musculoskeletal
Extremity, lower (gait) 2 0 0
Pain
Pain (musculoskeletal) 4 0 0
Dermatology
Pruitis 1 0 0
Number of patients with possibly drug-related events, N = 10.
Table 5. Summary of Response and Time to Progression, N = 10.
Patient Number Time to PSA
Progression (days)
PSA Progression
Occurred
PSA Response Response Duration
(days)
1 14 Yes No –
2 21 Yes No –
3 7 Yes No –
4 7 Yes No –
5 77 No Yes 29
6 632 No No* –
7 74 Yes No –
8 14 Yes No –
9 292 Yes No –
10 7 Yes No –
*Patient 6 had an unconfirmed (single value) PSA response with censored duration of 471 days.
Figure 1. Acetylated histone 3 as a percentage of total histone 3
over time. Values are averages of n = 8 patients ± SE.
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for samples corresponding to VPA greater than 46 mg/L (P < .001).
Prostate-specific antigen was higher when VPA exposure did not ex-
ceed 55 days, geometric mean = 55.0 ng/ml, compared with PSA
values from samples corresponding to greater than 55 days of VPA
exposure, geometric mean = 9.0 ng/ml (P < .001).
Conclusions
In this study, we administered a putative HDAI (oral VPA) to pa-
tients with CRPC. There is preclinical data from several laboratories
that suggests that VPA has anticancer activity in vitro and in vivo
[23,24]. In the current study, we used an intensive biomarker strat-
egy to explore the potential efficacy for oral VPA in prostate cancer.
We were interested in exploring the therapeutic potential of this
agent in prostate cancers.
We noted that oral VPA was difficult to administer reliably to older
patients with prostate cancer. The median age of our patients on
trial was 71 years, and this patient population experienced high degree
of short-term (neurologic) or long-term (fatigue) toxicity from oral
VPA. In addition, it was difficult to use total or free serum VPA
levels to guide us during this trial. Total and free serum VPA levels
did allow us to prevent severe toxicity from oral VPA as we did not
have grade 3 or 4 toxicity, but we were unable to use these levels
to guide us in preventing prolonged grade 1 or 2 toxicities. Base on
safety observations, the trial was discontinued early.
Although we treated only 10 patients with prostate cancer, several
interesting trends emerged from the study because intensive bio-
marker analysis was carried out. Surprisingly, 2 (20%) of 10 patients
had PSA responses to oral VPA, and this was durable in 1 patient.
When we designed the trial, we were concerned that VPA would
alter testosterone levels, causing PSA levels to rise or fall depending
on the T levels. Thus, we repeatedly measured serum testosterone,
although all patients had medical or surgical castration. Although
there were interesting fluctuations in the testosterone levels that we
initially reported were related to PSA level [29], final analysis of the
data shows that such fluctuations did not statistically influence the
PSA levels.
Nevertheless, PSA levels correlated inversely with total VPA levels.
This relationship was confirmed by many statistical analyses and was
also strongly positive in a multivariate analysis.
In addition, we measured histone acetylation in lymphocytes. We
were unable to detect reliable histone acetylation in the peripheral
blood in this current trial. Based on these observations, it is likely
Figure 2. Prostate-specific antigen as percent of baseline versus time on study therapy (truncated at 100 days).
Table 6. Spearman Correlation Coefficients for PSA, VPA, and Testosterone.
Total VPA Free VPA Testosterone Time
PSA Correlation −0.54 −0.32 −0.30 −0.49
P <.001 .002 .003 <.001
N 98 94 94 109
Figure 3. Waterfall plot showing maximal PSA decrease as a per-
cent of baseline. For each patient, the minimum among all post-
baseline PSA values was identified and expressed as a percent
change from baseline. This is interpreted as the best PSA re-
sponse. For patients with a postbaseline nadir, plotted values
are maximum PSA decrease. For patients without a postbaseline
nadir, plotted values are minimum PSA increase.
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that the effect on PSA is unlikely to be related to HDAC inhibition).
Valproic acid has been shown to induce differentiation of cancer cell
lines and leukemia cells in vivo, and this may be a putative anticancer
mechanism in this study. Conversely, as demonstrated by Xia et al.,
chronic low-dose administration (as opposed to acute administration)
of VPA has significant antitumor activity. Our observations are con-
sistent with this preclinical observation. There is a small possibility
that tumor HDAC inhibition was observed regardless of lack of acet-
ylation in peripheral lymphocytes. However, this is quite unlikely be-
cause we have seen comparable levels of acetylation ex vivo in
lymphocytes treated with oral VPA (manuscript in preparation).
In a recent study of VPA in solid tumors [30], 26 patients with
pretreated and progressive malignant disease were enrolled in escalat-
ing dose-level cohorts of 3 patients. The patients received VPA as a
1-hour infusion split in two doses daily for 5 consecutive days. After
a 2-week therapy-free interval, the treatment was repeated. The start-
ing dose in this study was 30 mg/kg per day and escalated to 60, 75,
90, and 120 mg/kg. The main toxicity was neurological (grade 3/4)
occurring in 9 of 26 patients at dose levels of 75, 90, and 120 mg/kg.
No hematological toxicity grade 3/4 toxicity was observed. The max-
imum tolerated dose of infusional VPAwas 60 mg/kg. Biomonitoring
of peripheral blood cells demonstrated the induction of hyperacety-
lation in most patients. Neurotoxicity was the dose-limiting factor of
infusional VPA in the treatment of patients with advanced cancer.
In our current study, we administered VPA orally because oral VPA
is used commonly as an antiseizure medication, and patient conve-
nience would be higher with an oral route of administration. Pharma-
cokinetic differences would seem to favor an intravenous route of
administration but this strategy is potentially limited by inability to
modulate HDACs on a continuous basis.
In summary, oral VPA can be administered to CRPC patients with
resultant PSA responses. Total VPA levels and duration of VPA ex-
posure were independent predictors for declining PSA. However,
oral VPA is not well tolerated in this patient population because of
grade 1 and 2 neurologic symptoms and fatigue. Total and free VPA
levels are useful for preventing severe toxicities from oral VPA but are
unable to protect against lower-grade toxicities. It is unlikely that
PSA responses from oral VPA are related to HDAC inhibition but
are likely to be due to alternative mechanisms. Further development
of oral VPA in prostate cancers is not recommended using an oral
formulation. Finally, an intensive biomarker strategy is useful to de-
velop clinical hypotheses in patients with CRPCs.
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